Danish pharmaceutical company Novo Nordisk A/S (NVO) said Tuesday it has submitted a label extension application to the European Medicines Agency or EMA for the existing marketing authorisation for Ozempic to introduce a new dose of 2.0 mg.
Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults.
The application submission is based on the results from the SUSTAIN FORTE trial that included 961 people with type 2 diabetes requiring treatment intensification.
In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1.0 mg. Both doses of semaglutide appeared safe and well-tolerated in the trial.
The most common adverse events in the trial were gastrointestinal, with the vast majority being mild to moderate that diminished over time and were consistent with the GLP-1 receptor agonist class.
Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg.
"Following the announcement of the headline results in November, we have expeditiously prepared the submission file. The submission in the EU represents an important milestone for people living with type 2 diabetes who have poor glycaemic control and need treatment intensification" said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.